Pear Therapeutics (Pear Therapeutics) Price-to-Owner-Earnings : (As of May. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-05), Pear Therapeutics's share price is $0.0001. Pear Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Pear Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

PEARQ's Price-to-Owner-Earnings is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 20.72
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-05), Pear Therapeutics's share price is $0.0001. Pear Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.54. Therefore, Pear Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-05), Pear Therapeutics's share price is $0.0001. Pear Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.84. Therefore, Pear Therapeutics's PE Ratio without NRI for today is At Loss.

Pear Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Pear Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Price-to-Owner-Earnings Chart

Pear Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Price-to-Owner-Earnings

Pear Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Price-to-Owner-Earnings	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Pear Therapeutics's Price-to-Owner-Earnings

For the Health Information Services subindustry, Pear Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pear Therapeutics's Price-to-Owner-Earnings Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's Price-to-Owner-Earnings falls into.

Pear Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pear Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.0001	/	0.00
	=

Pear Therapeutics (OTCPK:PEARQ) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Pear Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Pear Therapeutics (Pear Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 State Street, 13th Floor, Boston, MA, USA, 02109

Website

https://www.peartherapeutics.com

Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.

Executives

5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner	officer: Chief Product Dev. Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg	officer: Chief Commercial Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien	officer: General Counsel & Secretary	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey	director, officer: President and CEO	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich	officer: Chief Medical Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow	officer: Chief Accounting Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre	officer: CFO, COO, Treas., & Asst. Sec.	65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery	officer: Chief People Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks	director	C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman	director	6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc	10 percent owner	195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891